Each year, the ATS unites innovators, investors, clinicians, and advocacy groups who are leading the efforts to develop powerful new treatments for deadly and crippling diseases of the lungs and airways at the annual Respiratory Innovation Summit. The 2024 RIS will be hosted on Friday, May 17, and Saturday, May 18, at the Manchester Grand Hyatt San Diego.

This meeting historically attracts more than 375 global leaders representing all facets of the respiratory industry, including representatives from start-ups, business development, venture capital, government, academia, and clinical medicine. All companies innovating in pulmonary, critical care, or sleep medicine are encouraged to apply.

“Lassen Therapeutics is a clinical-stage biotech developing novel antibodies aiming to address unmet needs in fibro-inflammatory disorders such as thyroid eye disease, IPF, and oncology. Therefore, any venue where we can share our program data with the broader pharma, biotech, and investor community is incredibly beneficial for us,” said Lassen Therapeutics Vice President of Fibrosis and Translational Biology and former RIS participant Jamie Swaney, PhD. “The RIS has been great in providing this level of increased exposure for our company. Aside from the business development benefits, RIS always assembles the best-of-the-best in terms of industry and academic leaders in the pulmonary field, so the level of scientific discussion and feedback is top-notch.”

The planning committee will select 75 companies to be featured for poster presentations. Among the 75 selected organizations, 20 will be spotlighted for six-minute oral presentations. The RIS agenda also includes a venture capital panel, angel investor panel, business development panel, and plenty of time for networking.

“RIS provided a unique opportunity for Apnimed to showcase our clinical program of research to a diverse audience,” explained Apnimed Senior Vice President of Clinical Development and previous RIS participant John Cronin, MD. “We are developing a first-in-class therapeutic, so it is critical for us to articulate our mission, science, and vision. We received valuable feedback from a variety of scientists, pharmaceutical executives, and VCs.”

RIS registrants will be invited to attend a networking reception and dinner with a keynote address on Friday. On Saturday, the program will include a full day of programming, continental breakfast, lunch, dedicated networking time, and a closing reception. The full agenda for the meeting can be found on the conference website, conference.thoracic.org.

The summit is a NON-CME program.

RIS registration is located in the same system as ATS 2024 International Conference registration, either as a single event or as an additional fee to attendees’ ATS 2024 overall registration. RIS attendance does not include or require full registration for ATS 2024, but attendees are encouraged to be a part of the larger ATS community. RIS attendees are encouraged to take advantage of the hotel blocks offered during the event.

The ATS gratefully acknowledges the members of the RIS Advisory Board and Planning Committee, who donated their time to develop this pioneering event.

To secure or inquire about sponsorship opportunities at the RIS or learn more about the RIS, contact Dustin Bell at [email protected].